leisure time -WSS

leisure time

author：entertainment 2025-10-02 10:45:28 - browse：8

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： UCB departs biotech trade group BIO

entertainment

WSS

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

3 medical device trends to watch in 2024

Ahead of JPM, here's who's profiting most in health care

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Texas Department of Public Safety speaks out on migrant abuse allegations

How a scoliosis diagnosis changed the life of one young dancer

explore

leisure time

knowledge

Alkermes shareholders re

JPM: CVS says Medicare Advantage patients are impacting profits

New air purifier tech could be key to improving indoor air quality

Feng Zhang, Grail founder join forces on new gene editing startup

Dobbs anniversary: the lost opportunity of abortion as health care

J&J to buy cancer drug developer Ambrx Biopharma

George Santos makes 1st court appearance after pleading not guilty to 13 counts

3 trends to watch in health tech's hiring outlook for 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The FDA must approve intranasal treatments for anaphylaxis

focus

Antibiotic resistance and the global rise in human conflict